Guo et al. used a size-based microfluidic system to detect HE4+ CTCs in patients with suspicious ovarian cancer and showed a sensitivity of 73.3% and a specificity of 86.7% [47]. This evidence concerns the gene WFDC2 and ovarian carcinoma.